2024-10-22 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report

**Company Overview:** AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and markets pharmaceuticals, including Humira, a blockbuster drug for rheumatoid arthritis and other autoimmune diseases.

**Performance Analysis:**

**1. Relative Performance:**

* **Cumulative Return:** ABBV has generated a cumulative return of 142.51% compared to 136.39% for the S&P 500 (VOO).
* **Outperformance:** ABBV has outperformed the S&P 500 by 6.12%, which represents a relative outperformance of 48.52% based on historical data (where 100% represents the maximum outperformance and 0% represents the minimum).

**2. Recent Price Movement:**

* **Closing Price:** $186.58
* **Moving Averages:**
    * 5-Day Moving Average: $188.2
    * 20-Day Moving Average: $192.85
    * 60-Day Moving Average: $193.13

The stock is currently trading below its 5, 20, and 60-day moving averages, indicating a short-term downtrend.

**3. Technical Indicators:**

* **RSI:** 21.76 (Oversold). A reading below 30 suggests the stock is oversold, potentially indicating a bounce back in the near future. 
* **PPO:** -0.51 (Negative). A negative PPO suggests the stock is currently in a downtrend. 
* **Delta_Previous_Relative_Divergence:** -12.77. A negative value suggests a short-term downtrend in relative performance. 
* **Expected_Return:** 5.4%. This indicates a potential for outperformance compared to the S&P 500 over the long term (2+ years).

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |
| 2023-07-27 | 2.91 | 2.79 |

The most recent earnings report showed that ABBV exceeded analysts' expectations for EPS. This positive result suggests that the company is continuing to perform well, potentially supporting the stock price.

**5. News and Recent Issues:**

* **Recent Market Outlook:** Market analysts remain generally optimistic about ABBV's future prospects, citing its strong drug portfolio, including Humira, and its pipeline of new drug candidates.
* **Analyst Opinions:** Most analysts rate ABBV as a "buy" or "hold," with some recommending a "strong buy." The average price target for the stock is $190-$200, suggesting potential upside from current levels. 
* **Performance Highlights:** ABBV's consistent performance and strong earnings have contributed to its steady growth over the past few years. 

**6. Overall Analysis:**

ABBV has historically outperformed the S&P 500 and continues to demonstrate strong earnings performance. While recent technical indicators suggest a short-term downtrend, the stock may be oversold and poised for a potential bounce. Long-term investors might consider ABBV as a potential addition to their portfolio due to its strong fundamentals and future growth prospects. However, investors should monitor market conditions and technical indicators closely for potential short-term volatility.

**7. Disclaimer:** This analysis is for informational purposes only and should not be considered investment advice. Consult with a financial professional before making any investment decisions. 
